MSPs get to benefit from every important IT trend that comes along, whether that's cybersecurity or data and AI,' said FFL's ...

Abacus Group and Medicus IT, two leading providers of IT managed services with deep subject matter expertise in the highly ...

FFL Partners ("FFL"), a private equity firm focused on growth investments in tech-enabled business services and healthcare companies, today announced the completion of the merger of FFL portfolio ...

Medicus Pharma offers high-risk, high-reward potential, with its novel SkinJect patch for basal cell carcinoma and Antev ...

Healthcare and tech company bosses, including the co-founders of the ASX’s newest $30 billion company Pro Medicus, dominate ...

MDCX ’s lead asset is Skinkject, a patented innovative product intended to address the most commonly occurring cancer, which is skin cancer, or Basal Cell Carcinoma (BCC). Skinject is a thumb-sized ...

ASX 200 healthcare shares led the market last week, propelled by yet another share price surge for market darling Pro Medicus ...

Overall, Brits seem happy with their GP services, but they fared worst in the area of contact, with only around half (53%) of ...

Pro Medicus Ltd (ASX: PME) shares have risen 550% over the past three years. Have you missed the boat? Here are the views of 3 experts.

Pro Medicus (ASX: PME) won a contract with UCHealth of at least $170 million over 10 years, marking its second-largest ...

About Medicus Pharma Ltd: Medicus Pharma Ltd. (NASDAQ: MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets.